Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Conditions

• Metastatic Thyroid Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Cyclophosphamide — DRUG
  Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
• Sirolimus — DRUG
  Sirolimus 4 mg, PO, days 1-28

Study Details

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.

Key Dates

Start date

Apr 27, 2017

Status verified

Jul 2025

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

22 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Cyclophosphamide and Sirolimus
  Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19

Primary Outcome Measure

Percentage of patients that respond to treatment [ Time Frame: Patients will be followed for response until progression or up to 2 Years ]

Central Contacts

• Cancer AnswerLine
  1-800-865-1125
  [email protected]
• Paul Swiecicki, M.D.
  [email protected]

Locations (1)

Find similar trials in Ann Arbor, MI

Related Studies

• Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
  PHASE2 · Recruiting · Massachusetts General Hospital · Washington D.C., District of Columbia